Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 14/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 10/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 11/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31005090 | 1.00 | NOS3 (0.44) | NOS3NOS1NOS2ACHEMEN1 | |
| SCHEMBL2087614 | 0.96 | NOS3 (0.48) | NOS3NOS1NOS2ACHEMEN1 | |
| SCHEMBL6845547 | 0.86 | — | — | |
| SCHEMBL795850 | 0.76 | GRM4 (0.40) | NOS3NOS1NOS2ACHEGRM4 | |
| SCHEMBL24339083 | 0.74 | GRM4 (0.39) | NOS3NOS1NOS2ACHEMEN1 | |
| SCHEMBL540379 | 0.74 | GRM4 (0.39) | NOS3NOS1NOS2ACHEMEN1 | |
| SCHEMBL30406836 | 0.74 | GRM4 (0.39) | NOS3NOS1NOS2ACHEMEN1 | |
| SCHEMBL30406511 | 0.74 | GRM4 (0.39) | NOS3NOS1NOS2ACHEMEN1 | |
| SCHEMBL827623 | 0.74 | GRM4 (0.39) | NOS3NOS1NOS2ACHEGRM4 | |
| SCHEMBL25301798 | 0.74 | GRM4 (0.49) | NOS3NOS1NOS2ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307470-A | Synthesis method of 6, 7-dihydro-5H-cyclopenta [ b ] pyridine-4-amine | 上海毕得医药科技股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-118307470-A | Synthesis method of 6, 7-dihydro-5H-cyclopenta [ b ] pyridine-4-amine | 上海毕得医药科技股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2019072978-A1 | MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS | Basilea Pharmaceutica International AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| EP-1809622-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-21 | — | — | EP | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| EP-1809622-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006032631-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | NOS3 2353/4885NOS1 2019/4885NOS2 2767/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | NOS3 2353/4885NOS1 2019/4885NOS2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.